Skip to main content
Clinical Trials/NCT03435120
NCT03435120
Completed
N/A

Quality of Life Study in Patients With Breakthrough Cancer Pain Treated in Medical Oncology Services

Angelini Farmacéutica14 sites in 1 country118 target enrollmentDecember 21, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Breakthrough Pain
Sponsor
Angelini Farmacéutica
Enrollment
118
Locations
14
Primary Endpoint
Changes in quality of life of the patients
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

In cancer patients, pain is one of the most common symptoms. The range of reported prevalence of pain varies from 33% to 64% including different stages of cancer, during or after anticancer treatment. Moreover, despite the optimal management of basal chronic pain, 66% of these patients have reported breakthrough pain which has a severe impact on quality of life. There is insufficient clinical information on the quality of life of cancer patients with breakthrough pain treated in medical oncology services according to routine clinical practice. For this reason we consider it is appropriate to prospectively evaluate the quality of life of cancer patients with cancer breakthrough pain in medical oncology services as well as other factors that can affect quality of life. This post-authorization observational study will assess the quality of life of cancer patients with breakthrough cancer pain treated in medical oncology services in Spanish hospitals.

Registry
clinicaltrials.gov
Start Date
December 21, 2017
End Date
February 14, 2020
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Angelini Farmacéutica
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients \> 18 years
  • Patients with histologically confirmed neoplasia
  • Patients attended in medical oncology consultations
  • Life expectancy \> 3 months
  • Patients with baseline controlled cancer pain with opioids who are diagnosed of breakthrough cancer pain by Davies algorithm
  • Written informed consent

Exclusion Criteria

  • Untreated patients with opioids for baseline pain
  • Patients who are not opioid tolerant
  • Serious psychiatric disorder or any disease or condition that prevents the collection of data
  • Patients with evidence of opioid addiction or history of drug or alcohol abuse

Outcomes

Primary Outcomes

Changes in quality of life of the patients

Time Frame: Up to 4 weeks

Changes according to EQ-5D-5L questionnaire

Secondary Outcomes

  • Characteristics of patients(At baseline)
  • Management of cancer breakthrough pain.(Up to 4 weeks)
  • Anxiety and depression status and the possible relationship between these factors and quality of life.(Up to 4 weeks)
  • Sleep quality and the possible relationship between this factor and quality of life.(Up to 4 weeks)
  • Evaluate caregivers effort(Up to 4 weeks)
  • Perceived assistance quality by patients(Up to 4 weeks)
  • Improvement impression perceived by patients(Up to 4 weeks)

Study Sites (14)

Loading locations...

Similar Trials